LifeStance Health (LFST) EBITDA (2020 - 2026)

LifeStance Health has disclosed EBITDA across 7 years of filings, most recently posting $14.2 million for Q1 2026.

• In Q1 2026, EBITDA rose 3533.42% year-over-year to $14.2 million; the TTM figure through Mar 2026 stood at $22.6 million (up 159.57% YoY), while the FY2025 annual figure was $8.7 million, up 114.85% from the prior year.
• EBITDA improved to $14.2 million in Q1 2026, from $11.7 million in the prior quarter.
• Over the last five years, EBITDA for LFST reached as high as $14.2 million in Q1 2026 and fell as low as -$68.7 million in Q2 2022.
• The 5-year median for EBITDA is -$23.5 million (2024), against an average of -$25.6 million.
• Annual changes were most pronounced in 2022 — EBITDA sank 617.9% — and 2026, when it surged 3533.42%.
• A 5-year view of EBITDA shows it stood at -$46.6 million in 2022, then fell by 1.01% to -$47.0 million in 2023, then surged by 85.22% to -$7.0 million in 2024, then jumped by 267.79% to $11.7 million in 2025, then gained by 22.07% to $14.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered $14.2 million, $11.7 million, and $732000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.